Boston Scientific Co. (NYSE:BSX) Shares Acquired by Plato Investment Management Ltd

Plato Investment Management Ltd increased its position in shares of Boston Scientific Co. (NYSE:BSX) by 1,015.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,360 shares of the medical equipment provider’s stock after buying an additional 15,804 shares during the period. Plato Investment Management Ltd’s holdings in Boston Scientific were worth $1,189,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BSX. Eagle Bay Advisors LLC grew its position in shares of Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 309 shares in the last quarter. First Foundation Advisors acquired a new stake in shares of Boston Scientific during the first quarter worth $25,000. RiverPark Advisors LLC bought a new position in shares of Boston Scientific in the 1st quarter worth about $30,000. Northwest Investment Counselors LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at about $31,000. Finally, Sachetta LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director Charles J. Dockendorff sold 3,946 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total value of $286,874.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Charles J. Dockendorff sold 3,946 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total transaction of $286,874.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the completion of the sale, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The disclosure for this sale can be found here. Insiders sold a total of 51,837 shares of company stock worth $3,884,563 over the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX traded up $1.28 during mid-day trading on Thursday, hitting $75.16. 5,946,248 shares of the company’s stock were exchanged, compared to its average volume of 6,339,827. The company has a quick ratio of 1.14, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $79.43. The stock’s 50-day simple moving average is $76.43 and its 200-day simple moving average is $70.71. The firm has a market cap of $110.27 billion, a price-to-earnings ratio of 62.67, a price-to-earnings-growth ratio of 2.45 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. The firm had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. The company’s revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.53 EPS. On average, equities research analysts expect that Boston Scientific Co. will post 2.4 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on BSX. Robert W. Baird raised their target price on Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Canaccord Genuity Group increased their price objective on Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Barclays boosted their price target on Boston Scientific from $70.00 to $78.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research note on Thursday, July 25th. Finally, Citigroup raised their target price on shares of Boston Scientific from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $84.76.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.